HomeVideosTreatmentProjectsFriends
Site Wide RSS Feed


Home
Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
Newswise Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.
 
The trial will assess the safety and efficacy of a new investigational drug called VC-01, which was recently approved for testing by the U.S. Food and Drug Administration. The 2-year trial will involve four to six testing sites, the first being at UC San Diego, and will recruit approximately 40 study participants.
 
The goal, first and foremost, of this unprecedented human trial is to evaluate the safety, tolerability and efficacy of various doses of VC-01 among patients with type 1 diabetes mellitus, said principal investigator Robert R. Henry, MD, professor of medicine in the Division of Endocrinology and Metabolism at UC San Diego and chief of the Section of Endocrinology, Metabolism & Diabetes at the Veterans Affairs San Diego Healthcare System. We will be implanting specially encapsulated stem cell-derived cells under the skin of patients where its believed they will mature into pancreatic beta cells able to produce a continuous supply of needed insulin. Previous tests in animals showed promising results. We now need to determine that this approach is safe in people.
 
Development and testing of VC-01 is funded, in part, by the California Institute for Regenerative Medicine, the states stem cell agency, the UC San Diego Sanford Stem Cell Clinical Center and JDRF, the leading research and advocacy organization funding type 1 diabetes research.
 
Type 1 diabetes mellitus is a life-threatening chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow glucose to enter cells to produce energy. It is typically diagnosed during childhood or adolescence, though it can also begin in adults. Though far less common than Type 2 diabetes, which occurs when the body becomes resistant to insulin, Type 1 may affect up to 3 million Americans, according to the JDRF. Among Americans age 20 and younger, prevalence rose 23 percent between 2000 and 2009 and continues to rise. Currently, there is no cure. Standard treatment involves daily injections of insulin and rigorous management of diet and lifestyle.

Phase I/II clinical trials are designed to assess basic safety and efficacy of therapies never before tested in humans, uncovering unforeseen risks or complications. Unpredictable outcomes are possible. Such testing is essential to ensure that the new therapy is developed responsibly with appropriate management of risks that all medical treatments may present.
 
This is not yet a cure for diabetes, said Henry. The hope, nonetheless, is that this approach will ultimately transform the way individuals with Type 1 diabetes manage their disease by providing an alternative source of insulin-producing cells, potentially freeing them from daily insulin injections or external pumps.
 
This clinical trial at UC San Diego Health System was launched and supported by the UC San Diego Sanford Stem Cell Clinical Center. The Center was recently created to advance leading-edge stem cell medicine and science, protect and counsel patients, and accelerate innovative stem cell research into patient diagnostics and therapy.
 
Link:

Posted: 9/20/2014 5:28:18 AM by Miroslav | with 0 comments


Are you or a loved one interested in receiving stem cell treatment? For free information, please fill out our treatment form or email me don@repairstemcells.org and just put TREATMENT in the subject box and the MEDICAL CONDITION in the message.
Hong Kong LEmed, the specialist stem cell and laser therapy research and distribution group, announced today that it is supporting ALS research which uses Adult Stem Cells, the only stems cells to successfully complete clinical trials for incurable diseases.
 
Wan Chai, Hong Kong, September 15, 2014 -- Hong Kong LEmed (Leading Edge Medical Ltd.), the specialist stem cell and laser therapy research and distribution group, announced today that it is supporting ALS research which uses Adult Stem Cells, the only stems cells to successfully complete clinical trials for incurable diseases.
 
In view of the enormous amount of attention the ice bucket challenge has brought to ALS (Amyotrophic Lateral Sclerosis) often referred to as Lou Gehrig's Disease, LEmed is excited to be at the forefront of the revolutionary stem cell treatment technology used to fight this horrific disease.

Considering the fact that no effective long-term treatment exists for patients with ALS as well as a long list of neuro-inflammatory and neuro-degenerative disorders, LEmed has encouraged one of its lead doctors, Professor Shimon Slavin of Tel Aviv, to press forward with his adult stem cell technology.
 
Dr. Slavin is one of the only stem cell MD's in the world who has been successfully treating no-hope patients with a large variety of life threatening malignant and non-malignant indications for more than 20 years. The current research efforts in Tel Aviv is directed towards developing new approaches for regenerative medicine focusing on the use of multi-potent mesenchymal stromal cells (MSC) derived from either bone marrow or fat tissue (the patient own cells), or using unrelated placenta & cord tissue MSCs, derived from healthy newborn babies.
 
He has documented how, using new innovative technologies, that MSCs from all sources can be targeted to any part of the central nervous system by a non-invasive extra corporeal technology based on the use of low energy acoustic shockwave therapy. In parallel, they attempt to activate undifferentiated MSCs by multi-channel low energy laser light therapy, all of which are theoretically potentially beneficial to ALS patients and most likely to other indications of neuro-inflammatory and neuro-degenerative disorders.
 
The future goal is to use differentiated MSCs, both autologous and readily available allogeneic off-the-shelf, using differentiated placenta & cord tissue derived MSCs that were also shown to secrete neurotrophic factors that may help regulate the function of neurons in the brain and also play an important role in repairing or replacing damaged neurons. Such factors may also be therapeutically effective by activation of locally residing multi-potent stem cells located throughout the central nervous system, which otherwise do not respond to the body need.


LEmed strongly recommends supporting these research efforts that are the most promising by an experienced team that has already treated several hundreds of patients with ALS and a variety of other neuro-degenerative disorders and autoimmune diseases, thus far with undifferentiated MSCs. Clinical application of the next generation of cellular therapy depends on additional research to confirm the advantage of targeted, activated and also differentiated MSCs in comparison with current therapeutic approach based on the use of undifferentiated MSCs enriched in vitro.  Considering the genetic background of patients with familial type ALS and more subtle molecular abnormalities even in patients considered as sporadic ALS, and the practical need to have available readily available cells for treatment of patients with rapidly progressive disease, much attention will be given in the future to the use of young and normal MSCs derived from placenta & cord tissue of normal newborn babies of consenting mothers
 
Donations should be addressed to CordCure Ltd in Tel Aviv, Israel, earmarked for ALS Research.
 
Account Name: CordCure
Bank Poalim  Main Branch # 170 50 Rothchild Street Tel Aviv 61000
 
Account # 170-223405 Swift: POALILIT IBAN: IL880121700000000223405
 
About Leading Edge Medical Ltd.:
Cellular medicine is revolutionizing medical treatment in the 21st century and Leading Edge Medical's treatments are at the forefront of the field. Thousands of patients around the world have already benefited from bio-technologies using stem cells and intravenous laser therapy. Diseases once considered incurable are responding well to stem cell therapies and are restoring a quality of life to patients they thought they had lost forever.
 
LEmed is committed to applying modern day best practices to the growing field of regenerative medicine. With advanced medical treatment facilities offering personalized, ongoing care plans and the highest quality of customer service, we are dedicated to providing a better life for patients.


Contact:
Jeffery Tobin
Leading Edge Medical, Ltd
14F, 8 Hennessy Road
China Hong Kong Tower
Wan Chai, Hong Kong 999077
+852 21270684
info@healingmed.com
http://www.healingmed.com
Posted: 9/17/2014 4:02:15 PM by Miroslav | with 0 comments


Don Margolis

Stem Cell Treatment Now?

Click here to request information about what is NOW available for the disease You are interested in!
Bookmark this page to:Add to Twitter Add to Newsvine Add to MySpace Add to Link-a-Gogo Add to Multiply Add to MyAOL Add to Diigo Add to Yahoo Bookmarks Add to Yahoo MyWeb Add to Facebook Add to Mister Wong Add to Terchnorati Add to Segnalo Add to Digg Add to Google Bookmarks Add to Reddit Add to Faves Add to Blogmarks Add to StumbleUpon Add to Delicious